Andere Sprachen Hanall Biopharma Co., Ltd.

Aktien

A009420

KR7009420001

A009420

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 26.06.2024			% 5 Tage	% 1. Jan.
31.050 ^KRW	-3,27 %		-5,77 %	-29,91 %

14.05.	Hanall Biopharma Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
03.05.	HanAll Biopharma gibt den Beginn der randomisierten, doppelt-maskierten und vehikelkontrollierten Phase-III-Studie VELOS-4 zur Bewertung von Tanfanercept zur Behandlung des trockenen Auges bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases	29.05.
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies	28.05.
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03.05.
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13.06.23
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13.06.23
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	12.06.23
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01.05.23
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	30.03.23
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	16.03.23
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	13.02.23
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	13.02.23
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	10.02.23
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	09.12.22
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	16.11.22
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	11.10.22
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11.10.22
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04.10.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hanall Biopharma Co., Ltd.

Aktien

A009420

KR7009420001

A009420

Andere Sprachen

Filter